Hanauske, A R <br/><br/>
Dose intensity phase I/II trial with carboplatin, ifosfamide, etoposide and vincristine combined with filgrastim in patients with small-cell lung cancer.  [electronic resource] 

 -  Oncology   
 - 363-70 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article 
<br/><br/><label>ISSN: </label>0030-2414 
<br/><br/><label>Standard No.: </label>10.1159/000227719  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Agents, Alkylating--administration & dosage<br/>Antineoplastic Agents, Phytogenic--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Carboplatin--administration & dosage<br/>Carcinoma, Small Cell--drug therapy<br/>Drug Administration Schedule<br/>Etoposide--administration & dosage<br/>Feasibility Studies<br/>Female<br/>Filgrastim<br/>Granulocyte Colony-Stimulating Factor--therapeutic use<br/>Hematopoiesis--drug effects<br/>Humans<br/>Ifosfamide--administration & dosage<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Neutropenia--chemically induced<br/>Recombinant Proteins<br/>Thrombocytopenia--chemically induced<br/>Treatment Outcome<br/>Vincristine--administration & dosage